Author Login IJIRT Partner Network (IPN) Login

BIOMARKERS TO PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER

  • Unique Paper ID: 156858
  • Volume: 9
  • Issue: 5
  • PageNo: 205-221
  • Abstract:
  • Traditional treatment modalities for advanced cancer act directly on tumors to inhibit growth or destroy them. Along with surgery, these modalities are predominantly palliative, though associated with toxicity and modest improvements in survival of patients with advanced solid tumors. To address these issues, novel immunotherapies targeting programmed death-1 (PD-1/PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA4) have been developed and approved by the FDA. These therapies have been proven to provide substantial benefit and success in advanced solid tumors of different types. However, these expensive checkpoint inhibitor therapies extend clinical benefits to only a small subset of patients. Hence, it is crucial to comprehend the determinants and the role of biomarkers that drive response, resistance, and adverse effects. In this review, we have elaborated on the role of various biomarkers both pre-treatment and post-treatment which assist in predicting response to immune checkpoint inhibitors in cancer treatment.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 9
  • Issue: 5
  • PageNo: 205-221

BIOMARKERS TO PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry